

# Seth J Zost

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/819336/publications.pdf>

Version: 2024-02-01

28  
papers

6,587  
citations

430442

18  
h-index

552369

26  
g-index

45  
all docs

45  
docs citations

45  
times ranked

10395  
citing authors

#	ARTICLE	IF	CITATIONS
1	Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. <i>IScience</i> , 2022, 25, 103602.	1.9	6
2	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 490-495.	15.2	577
3	Real-time cell analysis: A high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape. <i>STAR Protocols</i> , 2022, 3, 101387.	0.5	8
4	Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. <i>Cell Host and Microbe</i> , 2021, 29, 44-57.e9.	5.1	937
5	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , 2021, 27, 717-726.	15.2	838
6	Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. <i>Cell</i> , 2021, 184, 2316-2331.e15.	13.5	321
7	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. <i>Cell</i> , 2021, 184, 1804-1820.e16.	13.5	297
8	An Egg-Derived Sulfated N-Acetylglucosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines. <i>MBio</i> , 2021, 12, e0083821.	1.8	8
9	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021, 596, 103-108.	13.7	222
10	Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. <i>Cell Reports</i> , 2021, 36, 109604.	2.9	67
11	Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	20
12	Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. <i>Cell Reports</i> , 2021, 37, 109784.	2.9	20
13	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. <i>Nature Microbiology</i> , 2021, 6, 1233-1244.	5.9	237
14	The Crossroads of Glycoscience, Infection, and Immunology. <i>Frontiers in Microbiology</i> , 2021, 12, 731008.	1.5	3
15	Pan-ebolavirus protective therapy by two multifunctional human antibodies. <i>Cell</i> , 2021, 184, 5593-5607.e18.	13.5	21
16	Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines During the 2017-2018 Season. <i>Clinical Infectious Diseases</i> , 2020, 71, 1447-1453.	2.9	27
17	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , 2020, 584, 443-449.	13.7	956
18	Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. <i>Nature Medicine</i> , 2020, 26, 1422-1427.	15.2	450

#	ARTICLE	IF	CITATIONS
19	Human Influenza A Virus Hemagglutinin Glycan Evolution Follows a Temporal Pattern to a Glycan Limit. <i>MBio</i> , 2019, 10, .	1.8	74
20	Identification of Antibodies Targeting the H3N2 Hemagglutinin Receptor Binding Site following Vaccination of Humans. <i>Cell Reports</i> , 2019, 29, 4460-4470.e8.	2.9	22
21	Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens. <i>Journal of Infectious Diseases</i> , 2019, 219, S38-S45.	1.9	67
22	Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin. <i>ELife</i> , 2019, 8, .	2.8	80
23	Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. <i>Nature Communications</i> , 2018, 9, 3361.	5.8	189
24	Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 12578-12583.	3.3	437
25	A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. <i>PLoS Pathogens</i> , 2017, 13, e1006682.	2.1	188
26	Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013â€“2014 influenza season. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15798-15803.	3.3	203
27	Standardized Two-Step Testing of Antibody Activity in COVID-19 Convalescent Plasma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
28	Identification of Antibodies Targeting the H3N2 Hemagglutinin Receptor Binding Site Following Vaccination of Humans. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1